According to a TRM Labs report, illicit flows reached about $154–158 billion in 2025, and regulators increased pressure ...

An announcement from Aptose Biosciences ( (TSE:APS)) is now available. Aptose Biosciences Inc., a clinical-stage biotech developer of precision oncology drugs focused on hematologic malignancies, is ...

Abizer Diwanji, Founder of NeoStrat Advisors LLP, and Sachin Dixit, Lead Internet Research Analyst at JM Financial ...

April 29 (Reuters) - British luxury carmaker Aston Martin on Wednesday reported a narrower first-quarter, loss helped by ...

Aston Martin Lagonda Global (LON:AML) reported first-quarter 2026 results in line with its guidance and maintained its ...

WorkFusion, a UiPath Company, a pioneer in AI agents for financial crime compliance (FCC), today announced that Everest Group has ranked WorkFusion #5 in the Everest Group Top 50™ FCC Technology ...

AI doesn't think — it calculates. A blockchain dev explains why blind trust in chatbots erodes critical thinking and invites ...

As Australian banks lean further into AI, the asset manager has identified the sector as being largely insulated from ...

List of crypto exchanges in Indonesia for beginners, pro traders. Quickly compare supported cryptos, KYC levels, regulatory ...

Sellas Life Sciences shares rose after Commonwealth Equity Services boosted its stake ahead of a key Phase 3 AML trial milestone, joining other major institutional investors in increasing holdings.

“Guidance remains at total R&D plus SG&A expenses in 2026 of approximately $400 million, excluding the impact of $50 million in estimated non-cash stock compensation expense,” CFO Keith Goldan said.

Cullinan Therapeutics, Inc. has a cash-rich balance sheet and no financial debt while trading at a reasonable valuation. Read ...